Addex Therapeutics Ltd advanced its clinical portfolio in the three months to 30 September bringing its lead product dipraglurant a step closer to registration for patients suffering from dyskinesia associated with the use of levodopa to treat Parkinson’s disease. Dipraglurant is a small molecule allosteric modulator which is currently in a Phase 2b/3 pivotal study. Altogether, the company has three programmes in the clinic in addition to a research collaboration with Indivior Plc into treatments for addiction disorders.
